Nakajima M, Goh Y, Azuma I, Hayaishi O
Department of Ophthalmology, Osaka Medical College, Japan.
Graefes Arch Clin Exp Ophthalmol. 1991;229(5):411-3. doi: 10.1007/BF00166301.
The effects of topically applied prostaglandin (PG) D2 and BW245C, a potent PGD2 agonist, on intraocular pressure (IOP) were studied in normotensive human volunteers. Doses of 5 and 10 micrograms PGD2 induced a mean reduction in IOP of 0.8 and 1 mmHg, respectively. At a dose of 50 micrograms, hypotension was preceded by initial hypertension (4 mmHg at 0.5 h) and the magnitude of the mean IOP reduction during the hypotensive phase was 1.1 mmHg. The application of BW245C (2.5 micrograms) induced an IOP change similar to that observed following treatment with 50 micrograms PGD2. Side effects caused by these compounds included conjunctival hyperemia, itching, and foreign-body and mild burning sensations. However, miosis and signs of intraocular inflammation were not observed. These results indicate that although PGD2 and BW245C are effective in reducing human IOP, their clinical usefulness as anti-glaucoma drugs may be limited by the extraocular side effects.
在血压正常的人类志愿者中研究了局部应用前列腺素（PG）D2和强效PGD2激动剂BW245C对眼压（IOP）的影响。5微克和10微克剂量的PGD2分别使IOP平均降低0.8和1毫米汞柱。在50微克剂量时，低血压之前先出现初始高血压（0.5小时时为4毫米汞柱），低血压阶段IOP平均降低幅度为1.1毫米汞柱。应用BW245C（2.5微克）引起的IOP变化与用50微克PGD2治疗后观察到的变化相似。这些化合物引起的副作用包括结膜充血、瘙痒、异物感和轻度烧灼感。然而，未观察到瞳孔缩小和眼内炎症迹象。这些结果表明，尽管PGD2和BW245C在降低人类IOP方面有效，但它们作为抗青光眼药物的临床实用性可能会受到眼外副作用的限制。
